Genmab to acquire Merus in $8B deal

Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns.

Editor's Pick

Top Story Genmab to Pay $8B to Get Its Hands on Merus Head & Neck Cancer Drug With Blockbuster Potential Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns. Sponsored The Payer's Playbook: Stop the Data Chaos, Start Saving Now. Presented by Veradigm Don't let outdated systems dictate your future. Download your free copy of Redefining Payer Operations now and start leveraging data to build a more efficient, effective, and financially robust organization. ➡️ [ DOWNLOAD THE FREE EBOOK NOW ] ⬅️

Featured News

What Healthcare Tech Has Leaders Most Energized Right Now? During a recent panel discussion, healthcare leaders highlighted that the true promise of technology lies in ensuring that tools are practical, trusted and widely usable for both patients and clinicians. Pluto Health Expands Care Model to Medicare, Medicaid and Major Commercial Plans Pluto Health is now working with Medicare, Medicaid and commercial plans like UnitedHealthcare, Aetna, Blue Cross Blue Shield, Ambetter and Cigna. Induced Mesenchymal Stem Cells: A New Frontier in Ovarian Cancer Treatment Ovarian cancer urgently needs bold, transformative treatment approaches – not just small, incremental improvements. Synthetic, allogeneic iMSCs as tumor-targeting delivery vehicles are an example of how cell biology and engineering may unite and overcome longstanding oncology challenges. I Didn't Dedicate My Career to Medicine to Manage Paperwork — And AI Scribes Won't Fix That What clinicians really need today is comprehensive support to offload routine tasks. They need intelligent systems that can proactively highlight relevant patient history before appointments, flag care gaps, and automatically queue up appropriate screening reminders or preventive care protocols.

Video   Beyond Traditional, Broken Health Models Daniel Karlin, chief medical officer of MindMed, spoke at DiMe's Healthcare 2030 Summit in Washington, D.C. His company is developing novel treatments for brain health disorders, with a focus on psychiatry, neurology and addiction. Karlin urged healthcare leaders to look beyond existing data and assumptions to create more meaningful, systemic improvements.

Sponsored The Top-Rated Assistive Devices for Children With Sensory Processing Disorders Presented by Enabling Devices The best assistive devices for children with sensory processing disorders are those that meet their needs. They will enhance their ability to participate more fully in daily activities. Learn More.

Resources

Debunked Episode 19: Turmoil at the CDC, Epic's AI Strategy The latest episode of the Debunked podcast explores an ongoing debate questioning the role of payers in healthcare transactions. It also highlights turmoil at the CDC. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe